Dormax

Dormax 15 mg injection is administered intravenously (IV) or intramuscularly (IM). IV administration should be slow, over at least 2 minutes, and titrated to effect. Close monitoring of vital signs is essential.

Midazolam enhances the activity of gamma-aminobutyric acid (GABA), the main inhibitory neurotransmitter in the brain, by binding to GABA-A receptors. This leads to increased chloride ion influx, hyperpolarization of neurons, and reduced neuronal excitability, resulting in sedative, anxiolytic, hypnotic, anticonvulsant, and muscle relaxant effects.

• Hypersensitivity to midazolam or other benzodiazepines.
• Acute narrow-angle glaucoma.
• Severe respiratory depression or acute pulmonary insufficiency.
• Concomitant use with strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, clarithromycin) when oral midazolam is used.

Store below 25°C. Protect from light. Do not freeze. Keep out of reach of children.

Symptoms of overdose include somnolence, confusion, impaired coordination, diminished reflexes, coma, and respiratory depression. Management involves general supportive measures, maintaining a patent airway, monitoring vital signs, and intravenous fluids. Flumazenil, a benzodiazepine receptor antagonist, can be used to reverse the effects but should be used with caution, especially in patients on chronic benzodiazepine therapy or with seizure disorders.

Pregnancy Category D: There is positive evidence of human fetal risk, but the benefits from use in pregnant women may be acceptable despite the risk (e.g., if the drug is needed in a life-threatening situation or for a serious disease for which safer drugs cannot be used). Midazolam is excreted in breast milk; therefore, caution should be exercised when administered to a nursing mother. A decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.

• Hypersensitivity to midazolam or other benzodiazepines.
• Acute narrow-angle glaucoma.
• Severe respiratory depression or acute pulmonary insufficiency.
• Concomitant use with strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, clarithromycin) when oral midazolam is used.

Store below 25°C. Protect from light. Do not freeze. Keep out of reach of children.

Symptoms of overdose include somnolence, confusion, impaired coordination, diminished reflexes, coma, and respiratory depression. Management involves general supportive measures, maintaining a patent airway, monitoring vital signs, and intravenous fluids. Flumazenil, a benzodiazepine receptor antagonist, can be used to reverse the effects but should be used with caution, especially in patients on chronic benzodiazepine therapy or with seizure disorders.

Pregnancy Category D: There is positive evidence of human fetal risk, but the benefits from use in pregnant women may be acceptable despite the risk (e.g., if the drug is needed in a life-threatening situation or for a serious disease for which safer drugs cannot be used). Midazolam is excreted in breast milk; therefore, caution should be exercised when administered to a nursing mother. A decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.